What's Happening?
Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. The firm is encouraging investors who suffered losses between October 10, 2023, and December 26, 2025, to contact them. The investigation centers on allegations that Inovio and its executives made false or misleading statements regarding the manufacturing of their CELLECTRA device and the regulatory prospects of their INO-3107 Biologics License Application (BLA). The U.S. Food and Drug Administration (FDA) accepted Inovio's BLA for INO-3107 on a standard review timeline, rejecting the company's request for accelerated approval due to insufficient information. Following this announcement, Inovio's stock price fell significantly.
Why It's Important?
This investigation is significant as it highlights potential securities law violations by a major pharmaceutical company, which could have substantial financial implications for investors. The allegations suggest that Inovio may have overstated the regulatory and commercial prospects of its INO-3107 treatment, potentially misleading investors. The outcome of this investigation could lead to legal actions and financial restitution for affected shareholders. It also underscores the importance of transparency and accuracy in corporate communications, particularly in the pharmaceutical industry where regulatory approvals are critical to a company's success.
What's Next?
Investors have until April 7, 2026, to seek the role of lead plaintiff in the class action lawsuit. The lead plaintiff will represent the interests of the class in the litigation. Inovio plans to request a meeting with the FDA to discuss potential pathways for accelerated approval of INO-3107. The outcome of these discussions and the ongoing legal proceedings will be closely watched by investors and industry analysts. The case may also prompt other companies to review their disclosure practices to avoid similar legal challenges.
